GSK to exclusively license novel oral antifungal
European Pharmaceutical Review
MARCH 30, 2023
GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) from SCYNEXIS. It is the only oral antifungal US Food and Drug Administration (FDA)-approved treatment for VVC and reduction of RVVC.
Let's personalize your content